Dana-Farber Cancer Institute | Strategic Alliance Partners

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Paolo Tarantino, MD, PhD, discusses key data with ADCs in breast cancer that were presented at ASCO 2026.

Toni K. Choueiri, MD, discusses safety data from LITESPARK-022 in ccRCC.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

Sara M. Tolaney, MD, MPH, discusses research inspired by an analysis of first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Paolo Tarantino, MD, PhD, notes the emergence of TROP2-directed ADCs in first-line TNBC management and the sequencing questions their arrival raises.

Paolo Tarantino, MD, PhD, notes the implications of updated safety data with post-neoadjuvant T-DXd in high-risk, HER2-positive early breast cancer.

A collaborative research initiative will unite two comprehensive inflammatory breast cancer clinics.

Dr Tarantino discusses practice-informing data regarding antibody-drug conjugates in breast cancer that were presented at the 2026 ASCO Annual Meeting.

Dr Tolaney discusses the FDA approval of first-line sacituzumab govitecan plus pembrolizumab for locally advanced or metastatic PD-L1–positive TNBC.

Narjust Florez, MD, discusses a trilingual, multidisciplinary workshop that was held at the 2026 ASCO Annual Meeting.

Narjust Florez, MD, discusses how the FDA approval of zidesamtinib in locally advanced or metastatic ROS1-positive NSCLC is an example of the fast pace of clinical oncology.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Toni Choueiri, MD, discusses data from LITESPARK-022 in ccRCC.

A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.

Toni Choueiri, MD, discusses how he will utilize adjuvant belzutifan plus pembrolizumab in ccRCC after its FDA approval.

Matthew S. Davids, MD, MMSc, discusses how efficacy data for pirtobrutinib plus venetoclax and rituximab from BRUIN CLL-322 may affect relapsed/refractory CLL management.

Praful Ravi, MB, BChir, MRCP, discusses the design of the PSMAtrack study of changes in PSMA-PET during initial therapy in patients with mHSPC.

Praful Ravi, MB, BChir, MRCP, discusses the clinical utility of PSMA-PET in mHSPC.

Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 that may shake up the CLL treatment paradigm.

Praful Ravi, MB, BChir, MRCP, discusses data from the phase 4 PSMAtrack trial in mHSPC.

Promising data for zenocutuzumab in patients with advanced NRG1-positive cholangiocarcinoma were shown according to researchers at Dana-Farber.

A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

Alicia Morgans, MD, MPH, discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer.